Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1,304 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Seres Therapeutics Inc | MCRB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.015 | 2.12% | 0.7233 | 05:24:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.7083 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 12 | 1,304 | - | 0.54 - 5.83 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 05:30:12 | 24 | US$ 0.7085 | USD |
Seres Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 107.22M | 151.01M | - | 126.33M | -113.72M | -0.75 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Seres Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MCRB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.69 | 0.9292 | 0.6722 | 0.745073 | 5,238,433 | 0.0333 | 4.83% |
| 1 Month | 0.9153 | 1.17 | 0.5634 | 0.8128079 | 4,494,070 | -0.192 | -20.98% |
| 3 Months | 0.78 | 1.28 | 0.54 | 0.8335599 | 4,942,636 | -0.0567 | -7.27% |
| 6 Months | 1.02 | 2.05 | 0.54 | 1.00 | 4,818,802 | -0.2967 | -29.09% |
| 1 Year | 5.33 | 5.83 | 0.54 | 1.53 | 3,925,875 | -4.61 | -86.43% |
| 3 Years | 19.59 | 25.055 | 0.54 | 3.84 | 2,319,376 | -18.87 | -96.31% |
| 5 Years | 2.28 | 38.50 | 0.54 | 6.87 | 1,735,627 | -1.56 | -68.28% |
Seres Therapeutics Description
| Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. |
